arrow
C

Courtney W. Hudgens

The University of Texas MD Anderson Cancer Center
H指数:31
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Personalized targeting of BCL2 family proteins overcomes acquired resistance to BRAF-MEK inhibitors in preclinical melanoma

针对BCL2家族蛋白的个性化靶向策略可克服BRAF-MEK抑制剂在黑色素瘤模型中的获得性耐药

2026-06-260
OAAI
Retraction Note: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance

撤稿说明:sFRP2在衰老微环境中驱动黑色素瘤转移和疗法抵抗

Nature
IF48.5
2025-10-290
OAAI
Integrated analysis of molecular and clinical features associated with overall survival in melanoma patients with brain metastasis

黑色素瘤脑转移患者总体生存相关的分子和临床特征的综合分析

2025-04-150
OA
Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results (vol 9, pg 898, 2023)
2024-04-220
OAAI
Cancer testis antigen expression correlates with stromal natural killer cell activation and longer overall survival in small bowel neuroendocrine tumors
2024-03-220
PRE
Longitudinal spatial profiling reveals chemoresistance mechanisms and characteristics of minimal residual disease in high-grade serous ovarian cancer
2024-03-220
PRE
Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
2022-09-2717
OA
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy
Nature
IF48.5
2022-06-150
PRE
Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma
2021-11-069
OA
Multiplex Tissue Imaging Harmonization: A Multicenter Experience from CIMAC-CIDC Immuno-Oncology Biomarkers Network
2021-07-121
OAAI
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade

肠道菌群特征与联合CTLA-4和PD-1阻断的毒性有关

2021-07-08251
OAAI
PARP and CDK4/6 Inhibitor Combination Therapy Induces Apoptosis and Suppresses Neuroendocrine Differentiation in Prostate Cancer
2021-06-2233
OAAI
Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma
2021-03-1141
OA
The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell-Mediated Immunotherapies

谷氨酰胺酶抑制剂CB-839 (Telaglenastat) 增强T细胞介导的免疫疗法的抗黑色素瘤活性

2021-03-0286
OA
Clinical, molecular, metabolic, and immune features associated with oxidative phosphorylation in melanoma brain metastases

与黑色素瘤脑转移中氧化磷酸化相关的临床,分子,代谢和免疫特征

2021-01-0613
OAAI
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response

膳食纤维和益生菌影响肠道微生物组和黑色素瘤免疫治疗反应

Science
IF45.8
2021-01-010
OA
T-Cell Repertoire in Combination with T-Cell Density Predicts Clinical Outcomes in Patients with Merkel Cell Carcinoma
2020-11-0113
OAAI
Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma

空间分辨分析将基因组和免疫多样性联系起来,揭示黑色素瘤中不利的中性粒细胞活化

2020-04-1515
OAAI